Drugmaker BeyondSpring's Q3 net loss narrows to $1.7 mln
BeyondSpring reported a narrowed Q3 net loss of $1.7 million, down from $2.2 million last year. The company highlighted promising results for Plinabulin in NSCLC patients and secured $30 million in financing, achieving IND clearance for the RBM39 program. R&D expenses increased to $1.0 million for the quarter. BeyondSpring aims to advance Plinabulin’s clinical development for improved survival benefits.
)
Overview
- BeyondSpring Q3 net loss narrows to $1.7 mln from $2.2 mln last year
- Plinabulin shows promising results in NSCLC patients at SITC 2025 presentations
- SEED secures $30 mln financing, achieves IND clearance for RBM39 program
Outlook
- BeyondSpring emphasizes Plinabulin’s potential in resensitizing tumors resistant to checkpoint inhibitors
- Company highlights SEED’s IND clearance for RBM39 degrader program in the US and China
- BeyondSpring focuses on advancing Plinabulin’s clinical development for durable survival benefits
Result Drivers
- Research and development (R&D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Net -$1.70
Income mln
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
